MEK162 (ARRY-162), a Novel MEK 1/2 Inhibitor, Inhibits Tumor Growth Regardless of KRas/Raf Pathway Mutations

Array BioPharma

1.

Corresponding author: Array BioPharma, array.biopharma@cureus.com

Categories: Allergy/Immunology
Keywords:

How to cite this poster

Abstract
These data support the preclinical investigation of the effects of MEK inhibitors on apoptotic protein expression and the clinical investigation of MEK inhibitors in tumors with both wild-type and mutated Ras/Raf pathways